GELS — Gelteq Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1920092 ·
Australia
Last close
$0.55
Market Cap
$5.85M
52W High
$2.01
52W Low
$0.39
ADV30
6,003,373
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 20,125,518 | 9,349 | 5,923,891 |
| Jun 2025 | — | — | — | — | 21,475,155 | 344,648 | 5,670,669 |
| Dec 2024 | — | — | — | — | 25,115,456 | 3,046,602 | 6,321,693 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-21,883,487
Inventory
—
Receivables
$414,776
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$471,799
EBITDA
$-5,137,130
Free Cash Flow
$-4,751,912
Enterprise Value
$12,934,309
Total Cash
$9,349
Total Debt
$5,113,954
Shares Out
10,711,059
Trailing EPS
$-0.52
Book Value
$0.92
ROE
-42.9%
ROA
-17.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 165,645 | -4,951,089 | -6,645,453 | 21,475,155 | 5,670,669 | 15,804,486 | — |
| Jun 2024 | 0 | -2,607,661 | -3,546,195 | 20,757,827 | 5,645,530 | 15,112,297 | — |
| Jun 2023 | 79,843 | -3,379,662 | -3,506,220 | 22,494,636 | 3,836,144 | 18,658,492 | — |
| Jun 2022 | 147,536 | -3,194,274 | -3,368,891 | 23,408,790 | 2,553,396 | 20,855,394 | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACXP | Acurx Pharmaceuticals, Inc. | $5.84M | $1.36 | — |
| KAPA | Kairos Pharma, LTD. | $5.82M | $1.72 | — |
| PULM | Pulmatrix, Inc. | $5.88M | $1.61 | — |
| DRMA | Dermata Therapeutics, Inc. | $5.65M | $1.14 | — |
| XBIO | Xenetic Biosciences, Inc. | $5.60M | $2.39 | — |
News headlines (Yahoo Finance, 1h cache)
Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs
2026-06-17 12:30 · Yahoo
Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory Pathway
2026-05-20 12:00 · Yahoo
Gelteq Announces USD $3.5 Million Strategic Debt Financing to Accelerate Commercialization and Support Revenue Growth
2026-05-12 12:00 · Yahoo
Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health Applications
2026-06-12 16:30 · Yahoo
Healthy Extracts Q1 2026 Net Revenue Up 73% to Record $1.6 Million, Driving Positive EBITDA
2026-05-14 12:35 · Yahoo
Gelteq Establishes Center of Excellence in China to Accelerate Product Development and Commercial Expansion
2026-06-04 13:08 · Yahoo
Q1 Virtual Investor Summit Presentations Now Available On Demand
2026-03-26 19:46 · Yahoo
Investor Summit Announces Q1 Presenter Line Up (Presentations 3/25, 1-on-1s 3/26)
2026-03-20 12:00 · Yahoo
Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership
2026-02-11 13:45 · Yahoo
Gelteq announces preclinical results on medicinal cannabinoid absorption
2026-01-14 14:16 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.